Literature DB >> 7673407

Increased basal glucose production in type 1 Gaucher's disease.

E P Corssmit1, C E Hollak, E Endert, M H van Oers, H P Sauerwein, J A Romijn.   

Abstract

To evaluate the metabolic effects of Gaucher's disease, glucose metabolism and parameters of fat metabolism were studied by indirect calorimetry and primed continuous infusion of [3-3H]glucose in seven clinically stable untreated patients with type 1 Gaucher's disease and in seven healthy matched control subjects. Studies were performed in the postabsorptive state. In Gaucher patients, resting energy expenditure was increased by approximately 24% (29.4 +/- 0.7 vs. 23.7 +/- 0.8 kcal/kg.day; P < 0.01). Glucose production was increased by approximately 30% in patients compared to controls (14.00 +/- 0.51 vs. 10.77 +/- 0.26; P < 0.01), although plasma glucose concentrations and net glucose oxidation were not different. Although C peptide concentrations were not different, insulin concentrations were slightly increased in Gaucher patients (P < 0.05). The differences in basal glucose production were not related to differences in plasma concentrations of insulin or other glucoregulatory hormones. In conclusion, the increase in basal glucose production is a remarkable feature of type 1 Gaucher's disease, which cannot merely be explained by endocrine mechanisms. Because Gaucher's disease is manifested within the liver in macrophages, but not in hepatocytes, altered intrahepatic regulatory mechanisms might be involved in this increase in glucose production.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673407     DOI: 10.1210/jcem.80.9.7673407

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Protein, glucose and energy metabolism in Gaucher disease type I.

Authors:  O A Bodamer; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

2.  Life expectancy in Gaucher disease type 1.

Authors:  Neal J Weinreb; Patrick Deegan; Katherine A Kacena; Pramod Mistry; Gregory M Pastores; Priscilla Velentgas; Stephan vom Dahl
Journal:  Am J Hematol       Date:  2008-12       Impact factor: 10.047

Review 3.  Sphingolipids: the nexus between Gaucher disease and insulin resistance.

Authors:  Maria Fuller
Journal:  Lipids Health Dis       Date:  2010-10-11       Impact factor: 3.876

4.  Assessment of Basal Metabolic Rate and Nutritional Status in Patients with Gaucher Disease Type III.

Authors:  Divair Doneda; Filippo P Vairo; André L Lopes; Alvaro Reischak-Oliveira; Pedro Schestatsky; Marino M Bianchin; Cileide C Moulin; Ida V D Schwartz
Journal:  JIMD Rep       Date:  2013-12-17

Review 5.  Gaucher disease: pediatric concerns.

Authors:  Deborah Elstein; Aya Abrahamov; Altoon Dweck; Irith Hadas-Halpern; Ari Zimran
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Evaluation of the Nutritional Status of Gaucher Disease Type I Patients under Enzyme Replacement Treatment.

Authors:  Paola Iaccarino Idelson; Enza Speranza; Maurizio Marra; Fabrizio Pasanisi; Rosa Sammarco; Ferruccio Galletti; Pasquale Strazzullo; Antonio Barbato
Journal:  Nutrients       Date:  2022-08-03       Impact factor: 6.706

7.  Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review.

Authors:  Divair Doneda; Cristina B Netto; Cileide C Moulin; Ida Vanessa D Schwartz
Journal:  Nutr Metab (Lond)       Date:  2013-04-09       Impact factor: 4.169

8.  Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.

Authors:  Avner Thaler; Shani Shenhar-Tsarfaty; Yanay Shaked; Tanya Gurevich; Nurit Omer; Anat Bar-Shira; Mali Gana-Weisz; Orly Goldstein; Meir Kestenbaum; Jesse M Cedarbaum; Avi Orr-Urtreger; Nir Giladi; Anat Mirelman
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.